Ryplazim Injection, Powder, Lyophilized, For Solution
Product Images NDC 70573-099

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Ryplazim (NDC 70573-099). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kedrion Biopharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ryplazim 01)

An instructional illustration showing a syringe inserted into the stopper of a vial, depicting the preparation of an intravenous injection solution from a lyophilized powder vial.*

FDA Label Image

Figure 2 (Ryplazim 02)

An instructional line drawing showing a hand holding a vial with a rubber stopper, demonstrating a twisting or rotating motion indicated by an arrow at the vial's base. The image likely illustrates a step in vial preparation or handling.*

FDA Label Image

Figure 3 (Ryplazim 03)

An instructional illustration showing two syringes, one on the left and one on the right. An arrow between the syringes points downward, indicating a transfer or connection process between the two devices.*

FDA Label Image

Figure 4 (Ryplazim 04)

An instructional line drawing depicting a hand holding a syringe with measurement markings, preparing or administering an injection. The illustration focuses on the syringe and part of the hand, suggesting steps in drug preparation or administration.*

FDA Label Image

Fig A (Ryplazim 05)

An instructional illustration showing a syringe needle inserted through the rubber stopper of a medicine vial, depicting the process of drawing or injecting liquid medication. The vial contains a liquid level visible near the bottom.*

FDA Label Image

Fig B (Ryplazim 06)

An instructional line drawing showing a hand grasping a vial, with an arrow indicating to rotate or twist the vial at its base. This likely demonstrates how to prepare or handle the Ryplazim injection vial before use.*

FDA Label Image

Fig C (Ryplazim 07)

An instructional diagram showing the process of pushing liquid from one syringe with a needle on top to another syringe below it. An arrow points downward from the top syringe to the bottom syringe illustrating the transfer of liquid between the two syringes.*

FDA Label Image

Fig D (Ryplazim 08)

An instructional line drawing showing a hand holding a syringe connected to tubing, illustrating a step in the preparation or administration of an intravenous injection.*

FDA Label Image

Principal Display Panel (68.8 mg Vial Label)

Ryplazim 68.8 mg vial label for intravenous injection, powder, lyophilized for solution. Contains human plasminogen. Single-dose vial, sterile, preservative-free. Manufactured by Prometic Bioproduction, Inc. and Prometic Biotherapeutics, Inc. Includes storage instructions and barcode.*

FDA Label Image

Principal Display Panel (68.8 mg Vial Carton)

Packaging label for Ryplazim 68.8 mg/vial injection, powder, lyophilized, for solution. The label states the active ingredient as plasminogen, human-tvmh. It includes usage instructions for intravenous use only, noting it is sterile, preservative-free, single-dose vial, and to discard unused portion. The label shows the US license number 2065, NDC 70573-099-02, and manufacturer information for Prometic Bioproduction, Inc. and Prometic Biotherapeutics, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.